RxDoctor Payments Data

Jonathan Gording

Corneal and Contact Management · Los Angeles, CANPI 1487792701

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Coopervision Inc. accounts for 71.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,221 and has fallen 70.7% since, to $358 in 2025.

$2,627in general payments, 2019–2025

Across 52 payments — averaging $50.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$2K
  • Glaukos Corporation$307
  • Alcon$134
  • Optos, Inc.$100
  • Staar Surgical Company$98
  • Abiomed$60
  • plus $49 from 1 others

What the payments were for

  • Food & beverage$2,52796%
  • Entertainment$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coopervision Inc.38$1,879
Glaukos Corporation3$307
Alcon7$134
Optos, Inc.1$100
Staar Surgical Company1$98
Abiomed1$60
Ivantis, Inc1$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,627 in reported general payments places this provider in the 65th percentile of 140 corneal and contact management providers in California.

See all corneal and contact management providers in California

Medicare billing

Part B allowed, 2024
$21,451
Medicare patients
110
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost33$386
Timolol Maleate12$0

Paid to pharmacies, not to this prescriber.

Other corneal and contact management in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →